Home' Australian Pharmacist : Australian Pharmacist February 2015 Contents Australian Pharmacist February 2015 I ©Pharmaceutical Society of Australia Ltd.
The PGA says the Government must
fully utilise Australia's 5,450 strong
community pharmacy network to
deliver better and more cost-effective
PGA National President George
Tambassis said last month that the
objective of the Government's Medicare
reform agenda should be to ensure
the best health outcomes for patients,
delivered with maximum efficiency for
'Australia's community pharmacy
network is the nation's most accessible
health infrastructure, highly trusted by
the public and staffed by true health
professionals. Around the world,
governments, hospitals, health insurers
and health professionals, including GPs,
are increasingly recognising that better
utilising pharmacies takes pressure off
the wider health system and provides
faster, better and cheaper access to
treatments and advice for patients,'
Mr Tambasis said.
'Already in Australia, community
pharmacies have proven their ability
in areas such as enhanced medication
support, diabetes services, asthma
management and blood pressure
monitoring. The outstanding success
of the recent flu vaccination pilot in
Queensland is the latest example of
how pharmacies can deliver high quality
and more convenient and cost-effective
services to patients.
'However, Australia is lagging many
other countries in terms of making
the most effective use of its highly
accessible physical pharmacy network
and the skills of its pharmacist
profession, working in close
collaboration with doctors and other
'The Government's Medicare reforms,
combined with the upcoming new
community pharmacy agreement, aged
care reforms, primary health networks
and potential changes to the private
health insurance rebate provide the
right climate to transform pharmacies
into true health destinations.'
Mr Tambassis said the PGA would
be pursuing a range of service
enhancements to deliver better
outcomes for patients and greater
efficiency in the health system.
He said that in most cases, opportunities
to deliver these services more cost-
effectively, including through the better
use of technologies, had not been
taken up, leading to increased costs for
governments and patients -- costs that
could be reduced significantly by better
utilising pharmacies and pharmacists.
'Pharmacy and pharmacists have the
proven capability and stand ready to
deliver this common sense approach,
taking the pressure off doctors, hospital
emergency departments and the wider
health system,' Mr Tambassis said.
part of the
Pharmacists are part of the
solution to ensuring the future
sustainability of Medicare
according to the Pharmacy Guild
of Australia (PGA).
Monash and Janssen
Monash University has signed a
research collaboration agreement with
Janssen-Cilag (Janssen), one of the
Janssen Pharmaceutical companies of
Johnson & Johnson.
The collaboration, facilitated by
Johnson & Johnson Innovation, Asia
Pacific, will focus on research at Monash
University to develop potential new
medicines to treat autoimmune
diseases and disorders.
The ability of the immune system
to discriminate between self and
non-self-tissues is a crucial aspect
of its function. The failure of some
immune cells to appropriately manage
this discrimination can result in
autoimmunity, which affects millions of
people worldwide with diseases such as
rheumatoid arthritis and psoriasis.
While there are medications on the
market that can be used to treat some
of these autoimmune diseases, there
remains a substantial need for the
development of new and improved
Funding from Janssen will
enable Monash University and
Janssen immunology scientists
to collaboratively research the
mechanisms that underlie autoimmune
diseases for the development of
new and highly innovative potential
Professor Jamie Rossjohn, from the
Department of Biochemistry and
Molecular Biology, will lead the research
team at Monash University on the three-
year research program.
'By understanding the molecular basis
for the trigger that causes autoimmune
diseases we can uncover opportunities
for novel immunotherapeutics,'
Professor Rossjohn said.
Links Archive Australian Pharmacist January 2015 Australian Pharmacist March 2015 Navigation Previous Page Next Page